About Vereniging Innovatieve Geneesmiddelen
VIG (Vereniging Innovatieve Geneesmiddelen) serves as a bridge between farmaceutical innovators, government and science to tackle shared challenges in health.
Represents 45 companies working on ‘medicines of tomorrow’.
Three core themes:
- Access to medication
- Appropriate/personalized Care
- Innovative climate/ecosystem
Collaborations with GHH-partners:
- CBG (College ter beoordeling van geneesmiddelen): partner in e-PIL pilot
- Health Holland (Topsector LSH): Carla Vos is member of this TopTeam and HH advisory board
- ZonMw/ Program ‘Goed Gebruik Geneesmiddelen’: Carla Vos in GGG-board
Overview of characteristics
Active in countries:
Not in specific separate countries, but active globally via; European wide bodies such as EFPIA (European Federation of Pharmaceutical Industries and Associations).
CoP (community of practice):
CoP2: Pandemic Preparedness
Themes and subthemes in CoP:
- Access to medication and vaccines: VIG works on a ‘future proof system’
- Appropriate / personalized care and use of medication: supports studies post-approval (dose reduction, real-world evidence) to optimize use , in public commentary. VIG code of conduct includes commitment to responsible use and transparency.
- Innovation climate/eco system: by affiliation with EFPIA and IFPMA, publications on the attractiveness of the Netherlands for life sciences, investment norms, and strong data protection policies.
- Sustainability/responsibility/environmental impact: co-founded Coalitie Duurzame Farmacie, co-signed Green Deal Duurzame Zorg, e-PIL pilot to reduce waste
These themes fit into CoP2 because Pandemic Preparedness asks for easy and equal access to medical care, for regulations, alignment globally, and ‘overuse of medication’ like antimicrobials relate to AMR-domain of CoP2.
Carla Vos emphasizes that health issues don’t respect borders, neither does AMR.
Type of organization:
Private, commercial business
Available resources:
- Knowledge & expertise: Access to new medicines and vaccines, appropriate use of medication, innovation (R&D, clinical research). Publications on analyses, position papers, policy dossiers on waiting times and more.
- Digital innovation & implementation: e-pil (electronic patient leaflet)
- Networks: VIG connects innovators, government, regulators, healthcare professionals and more. Part of multiple initiatives like DCRF, Coalition for Sustainable Pharmacy, Health Holland).
- Advocacy & influence: contributes to EU policy debates and is part of GHH (CoP2). Part of /committed to coalition between VWS and Zorginstituut to create a future-proof reimbursement system for new medicines. ‘VIG Medicijndialoog’: event where VIG discusses with VWS and Zorginstituut how to ensure faster patient access.
- Financial resources: Membership model and fees.
- Coordination capacity: coordination of multiple stakeholder pilots (for example e-PIL), CSR reporting